Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Having performed analytical validation studies, we are now assessing the clinical utility of the upgraded automated Bone Scan Index (BSI) in metastatic castration-resistant prostate cancer (mCRPC). In the present study, we retrospectively evaluated the discriminatory strength of the automated BSI in predicting overall survival (OS) in mCRPC patients being treated with enzalutamide.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • Memorial Sloan-Kettering Cancer Center
  • Weill Cornell Medical College
  • Göteborgs universitet
  • University of Copenhagen
  • Skåne University Hospital
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Urologi och njurmedicin
Originalspråkengelska
TidskriftEJNMMI Research
Volym6
Utgivningsnummer1
StatusPublished - 2016 mar 9
PublikationskategoriForskning
Peer review utfördJa

Relaterad forskningsoutput

Visa alla (1)